STRO Sutro Biopharma, Inc.
Sutro Biopharma, Inc. (STRO) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
Where they traded
Last open-market purchase: October 15, 2025 , by MATSUI CONNIE .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| MATSUI CONNIE | Director | Buy | 50,000 | $0.80 | $40.0K | 50,000 | |
| Chow Gregory K. | CFO | Buy | 19,750 | $0.81 | $16.0K | 19,750 | |
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER | Buy | 17,000 | $0.80 | $13.6K | 71,832 | |
| Chung Jane | Chief Executive Officer | Buy | 12,500 | $0.80 | $10.0K | 122,850 | |
| Pauling David | Chief Admin. Ofcr. & GC | Buy | 12,504 | $0.80 | $10.0K | 71,737 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.